The Japanese breast cancer society clinical practice guidelines for pathological diagnosis of breast cancer, 2022 edition
Naoko Honma, Masayuki Yoshida, Keiichi Kinowaki, Rie Horii, Yuka Katsurada, Yuya Murata, Ai Shimizu, Yuko Tanabe, Chikako Yamauchi, Yutaka Yamamoto, Hiroji Iwata, Shigehira Saji
Abstract
This article is an English digest of the guidelines for pathological diagnosis published in The Japanese Breast Cancer Society (JBCS) Clinical Practice Guidelines in Japanese by Kanehara & Co., Ltd. in July 2022. In the 2022 edition, six Reviews, eight Basic Questions (BQs), and six Future Research Questions (FRQs) were included. Unlike for other fields, no Clinical Question (CQ) was included because an interventional study is rarely performed in diagnostic pathology. BQs refer to routinely used pathological methods supported by extensive evidence. The BQs for human epidermal growth factor receptor 2 (HER2) and hormone receptors have been revised according to revised international guidelines. FRQs refer to relatively new areas or non-routine methods supported by less evidence. Two new FRQs have been established for PD-L1 and cancer gene panel testing.